Assessment of ER, PR & HER2-neu in carcinoma breast.

Abstract

Breast carcinoma is the commonest malignancy among women around the world.[1] Annually many cases of breast carcinoma are reported worldwide.[2] In India, it has become the most common carcinoma and replaced the cervical carcinoma in females, mainly in the urban areas.[3] Every year the incidence of breast carcinoma is increasing in India.[4] In India, most patients with breast carcinoma belong to middle to old age group.[5] The incidence of breast carcinoma increases with age and reaches its peak at menopausal age. Various histopathological parameters have prognostic significance in breast carcinoma. This includes histologic subtype, grade, lymph node status, Estrogen receptor/Progesterone receptor status, growth factor and its receptors.[6] It has been found that the assessments of immunohistochemical markers have assumed a significant role in influencing the clinical decisions about the treatment and it is helpful in accessing the prognosis of the patients in breast carcinoma.